The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies

Julie Marie Vose, Philip Jay Bierman, A. Kessinger, P. F. Coccia, J. Andersen, F. B. Oldham, C. Epstein, James Olen Armitage

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

To test the value of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic stem cell transplantation, we enrolled 12 patients with recurrent non-Hodgkin's lymphoma or Hodgkin's disease having an absolute granulocyte count less than 150 x 106/l on day 30 after autologous hematopoietic stem cell infusion in an open-label, non-randomized study. These patients were compared to 21 similar historical control patients who were not treated with colony stimulating factor. Overall, the patients treated with granulocyte-macrophage colony stimulating factor had a mean absolute granulocyte count of 704 x 106/l on day 44 after stem cell infusion compared to a mean absolute granulocyte count of 308 x 106/l in historical controls (p = 0.008). The number of documented bacterial and fungal infections occurring after day 30 (9 vs 0, p = 0.01) was significantly reduced in the study group. The toxicity attributed to the granulocyte-macrophage colony stimulating factor was minimal with only one patient experiencing chills. Recombinant human granulocyte-macrophage colony stimulating factor appears to be effective for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic transplantation for lymphoid malignancies, with most patients having accelerated granulocytic recovery and a reduced incidence of infections.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalBone marrow transplantation
Volume7
Issue number2
StatePublished - Jan 1 1991

Fingerprint

Hematopoietic Stem Cell Transplantation
Granulocyte-Macrophage Colony-Stimulating Factor
Granulocytes
Neoplasms
Therapeutics
Colony-Stimulating Factors
Chills
Mycoses
Autologous Transplantation
Hematopoietic Stem Cells
Hodgkin Disease
Bacterial Infections
Non-Hodgkin's Lymphoma
Stem Cells
Incidence
Infection

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{c60ff851da8c439da02e090b9aede08b,
title = "The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies",
abstract = "To test the value of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic stem cell transplantation, we enrolled 12 patients with recurrent non-Hodgkin's lymphoma or Hodgkin's disease having an absolute granulocyte count less than 150 x 106/l on day 30 after autologous hematopoietic stem cell infusion in an open-label, non-randomized study. These patients were compared to 21 similar historical control patients who were not treated with colony stimulating factor. Overall, the patients treated with granulocyte-macrophage colony stimulating factor had a mean absolute granulocyte count of 704 x 106/l on day 44 after stem cell infusion compared to a mean absolute granulocyte count of 308 x 106/l in historical controls (p = 0.008). The number of documented bacterial and fungal infections occurring after day 30 (9 vs 0, p = 0.01) was significantly reduced in the study group. The toxicity attributed to the granulocyte-macrophage colony stimulating factor was minimal with only one patient experiencing chills. Recombinant human granulocyte-macrophage colony stimulating factor appears to be effective for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic transplantation for lymphoid malignancies, with most patients having accelerated granulocytic recovery and a reduced incidence of infections.",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and A. Kessinger and Coccia, {P. F.} and J. Andersen and Oldham, {F. B.} and C. Epstein and Armitage, {James Olen}",
year = "1991",
month = "1",
day = "1",
language = "English (US)",
volume = "7",
pages = "139--143",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Kessinger, A.

AU - Coccia, P. F.

AU - Andersen, J.

AU - Oldham, F. B.

AU - Epstein, C.

AU - Armitage, James Olen

PY - 1991/1/1

Y1 - 1991/1/1

N2 - To test the value of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic stem cell transplantation, we enrolled 12 patients with recurrent non-Hodgkin's lymphoma or Hodgkin's disease having an absolute granulocyte count less than 150 x 106/l on day 30 after autologous hematopoietic stem cell infusion in an open-label, non-randomized study. These patients were compared to 21 similar historical control patients who were not treated with colony stimulating factor. Overall, the patients treated with granulocyte-macrophage colony stimulating factor had a mean absolute granulocyte count of 704 x 106/l on day 44 after stem cell infusion compared to a mean absolute granulocyte count of 308 x 106/l in historical controls (p = 0.008). The number of documented bacterial and fungal infections occurring after day 30 (9 vs 0, p = 0.01) was significantly reduced in the study group. The toxicity attributed to the granulocyte-macrophage colony stimulating factor was minimal with only one patient experiencing chills. Recombinant human granulocyte-macrophage colony stimulating factor appears to be effective for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic transplantation for lymphoid malignancies, with most patients having accelerated granulocytic recovery and a reduced incidence of infections.

AB - To test the value of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic stem cell transplantation, we enrolled 12 patients with recurrent non-Hodgkin's lymphoma or Hodgkin's disease having an absolute granulocyte count less than 150 x 106/l on day 30 after autologous hematopoietic stem cell infusion in an open-label, non-randomized study. These patients were compared to 21 similar historical control patients who were not treated with colony stimulating factor. Overall, the patients treated with granulocyte-macrophage colony stimulating factor had a mean absolute granulocyte count of 704 x 106/l on day 44 after stem cell infusion compared to a mean absolute granulocyte count of 308 x 106/l in historical controls (p = 0.008). The number of documented bacterial and fungal infections occurring after day 30 (9 vs 0, p = 0.01) was significantly reduced in the study group. The toxicity attributed to the granulocyte-macrophage colony stimulating factor was minimal with only one patient experiencing chills. Recombinant human granulocyte-macrophage colony stimulating factor appears to be effective for the treatment of delayed engraftment following high-dose therapy and autologous hematopoietic transplantation for lymphoid malignancies, with most patients having accelerated granulocytic recovery and a reduced incidence of infections.

UR - http://www.scopus.com/inward/record.url?scp=0026101474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026101474&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 139

EP - 143

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -